ALX Oncology Holdings reported a third-quarter 2026 net loss of $21,826 thousand, consistent with the $22,144 thousand loss recorded in the same period last year. The company maintains a cash position of $147,206 thousand as it advances its clinical pipeline, including the ALX2004 and ASPEN-09-Breast programs.
Q3 net loss of $21,826 thousand was roughly flat versus $22,144 thousand a year earlier, and quarterly R&D spending of $17,463 thousand was in line, so the results themselves are unremarkable. The weighted-average share count of 140,904,752 versus 53,577,066 a year ago signals substantial dilution, while cash of $147,206 thousand gives a long runway. The real price drivers are the promised catalysts: ALX2004 Phase 1 safety and early efficacy data in December 2026 and ASPEN-09-Breast topline data in 2H 2027.
- • ALX2004 Phase 1 dose-escalation safety and early efficacy data plus KOL webinar in December 2026
- • Topline data from approximately 120 patients in the Phase 2 ASPEN-09-Breast trial expected in 2H 2027
- • Weighted-average shares grew to 140,904,752 from 53,577,066, pointing to heavy dilution
- • Cash of $147,206 thousand will be consumed by ongoing trials with no revenue yet